Literature DB >> 1733094

Infectious entry pathway for canine parvovirus.

S Basak1, H Turner.   

Abstract

We have investigated whether canine parvovirus (CPV) infection involves a low pH-dependent entry pathway. The effects of two lysosomotropic bases, NH4Cl and chloroquine, on CPV entry were studied by immunofluorescence and ultrastructural and biochemical methods. In the presence of these reagents, input virions appear to accumulate in large vacuoles. Ultrastructural studies indicated that uptake of virions takes place predominantly in small uncoated vesicles that appear to fuse with larger vesicles. In the presence of NH4Cl, virions accumulate in the latter structures and their uncoating appears to be prevented. Viral DNA as well as antigen synthesis were found to be significantly inhibited in the presence of these reagents. In addition, inhibition of viral DNA and antigen synthesis appeared to be most extensive when NH4Cl was present from 30 min preinfection, whereas no significant inhibition was observed when the cells were treated after 2 hr postinfection. Thus, the results indicate that CPV requires exposure to low pH in an endosomal compartment to initiate a productive infection.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1733094     DOI: 10.1016/0042-6822(92)90002-7

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  24 in total

Review 1.  Pathways of cell infection by parvoviruses and adeno-associated viruses.

Authors:  Maija Vihinen-Ranta; Sanna Suikkanen; Colin R Parrish
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

2.  Bound simian virus 40 translocates to caveolin-enriched membrane domains, and its entry is inhibited by drugs that selectively disrupt caveolae.

Authors:  H A Anderson; Y Chen; L C Norkin
Journal:  Mol Biol Cell       Date:  1996-11       Impact factor: 4.138

3.  Low pH-dependent endosomal processing of the incoming parvovirus minute virus of mice virion leads to externalization of the VP1 N-terminal sequence (N-VP1), N-VP2 cleavage, and uncoating of the full-length genome.

Authors:  Bernhard Mani; Claudia Baltzer; Noelia Valle; José M Almendral; Christoph Kempf; Carlos Ros
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

4.  Reovirus variants selected for resistance to ammonium chloride have mutations in viral outer-capsid protein sigma3.

Authors:  Kimberly M Clark; J Denise Wetzel; Yingqi Gu; Daniel H Ebert; Stephanie A McAbee; Emily K Stoneman; Geoffrey S Baer; Yuwei Zhu; Gregory J Wilson; B V V Prasad; Terence S Dermody
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

5.  Mutations in reovirus outer-capsid protein sigma3 selected during persistent infections of L cells confer resistance to protease inhibitor E64.

Authors:  G S Baer; T S Dermody
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

6.  Cellular uptake and infection by canine parvovirus involves rapid dynamin-regulated clathrin-mediated endocytosis, followed by slower intracellular trafficking.

Authors:  J S Parker; C R Parrish
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

7.  Cytoplasmic trafficking of the canine parvovirus capsid and its role in infection and nuclear transport.

Authors:  M Vihinen-Ranta; W Yuan; C R Parrish
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

8.  Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors.

Authors:  J S Bartlett; R Wilcher; R J Samulski
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

Review 9.  Parvovirus glycan interactions.

Authors:  Lin-Ya Huang; Sujata Halder; Mavis Agbandje-McKenna
Journal:  Curr Opin Virol       Date:  2014-07-19       Impact factor: 7.090

10.  Avian reoviruses cause apoptosis in cultured cells: viral uncoating, but not viral gene expression, is required for apoptosis induction.

Authors:  Lucía Labrada; Gustavo Bodelón; Juan Viñuela; Javier Benavente
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.